JP2023507926A5 - - Google Patents

Info

Publication number
JP2023507926A5
JP2023507926A5 JP2022534833A JP2022534833A JP2023507926A5 JP 2023507926 A5 JP2023507926 A5 JP 2023507926A5 JP 2022534833 A JP2022534833 A JP 2022534833A JP 2022534833 A JP2022534833 A JP 2022534833A JP 2023507926 A5 JP2023507926 A5 JP 2023507926A5
Authority
JP
Japan
Prior art keywords
disorder
pharmaceutical composition
group
composition according
esketamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507926A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/062508 external-priority patent/WO2021137148A1/en
Publication of JP2023507926A publication Critical patent/JP2023507926A/ja
Publication of JP2023507926A5 publication Critical patent/JP2023507926A5/ja
Pending legal-status Critical Current

Links

JP2022534833A 2019-12-30 2020-12-29 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 Pending JP2023507926A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962954790P 2019-12-30 2019-12-30
US62/954,790 2019-12-30
PCT/IB2020/062508 WO2021137148A1 (en) 2019-12-30 2020-12-29 Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Publications (2)

Publication Number Publication Date
JP2023507926A JP2023507926A (ja) 2023-02-28
JP2023507926A5 true JP2023507926A5 (cg-RX-API-DMAC7.html) 2024-01-09

Family

ID=74106090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534833A Pending JP2023507926A (ja) 2019-12-30 2020-12-29 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画

Country Status (3)

Country Link
US (2) US12478592B2 (cg-RX-API-DMAC7.html)
JP (1) JP2023507926A (cg-RX-API-DMAC7.html)
WO (1) WO2021137148A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
WO2004004693A1 (en) 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
CN105534936B (zh) 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
WO2009137843A2 (en) 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
US20120225949A1 (en) * 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013138322A1 (en) 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
US9468611B2 (en) 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
US10555916B2 (en) 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
KR20220044380A (ko) 2013-04-12 2022-04-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
WO2015066172A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3272338B1 (en) 2014-04-17 2020-09-09 Develco Pharma Schweiz AG Oral dosage form of ketamine
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
KR102604397B1 (ko) * 2014-11-04 2023-11-21 아카디아 파마슈티칼스 인코포레이티드 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
CA2970065A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
EP3377050A4 (en) 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
WO2018079693A1 (ja) 2016-10-27 2018-05-03 国立大学法人 千葉大学 (s)-ノルケタミンおよびその塩の医薬品としての応用
WO2018102488A1 (en) 2016-11-30 2018-06-07 Wolfson Philip E Ketamine for the treatment of menstrually related symptoms
EP3641742B1 (en) 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
MX2020003546A (es) * 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP3923920A4 (en) 2019-08-05 2022-11-23 The Ketamine Research Foundation KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Similar Documents

Publication Publication Date Title
JP2025061458A (ja) R-ケタミンおよびその塩の医薬品としての応用
RU2317817C2 (ru) Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства
TWI342776B (en) Carbostyril derivatives and mood stabilizers for treating mood disorders
EP3890726A1 (en) Methods of treating neurological and psychiatric disorders
CN101208092A (zh) 用于处理精神障碍的方法和组合物
CN112702995A (zh) 治疗重度抑郁症的艾氯胺酮的治疗方案
AU2019293515B2 (en) Method of treating major depressive disorder
US20240065988A1 (en) Combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
WO2021137147A1 (en) Dosage regime with esketamine for treating major depressive disorder
KR20170104597A (ko) 신경근육, 신경퇴행, 자가면역, 발달 및/또는 대사 질환의 치료를 위한 뇌 유도된 신경친화성 인자(bdnf)의 유도된 발현
JP2021511365A5 (cg-RX-API-DMAC7.html)
JP2024531437A5 (cg-RX-API-DMAC7.html)
JP2022536653A (ja) 老化関連分泌表現型を修整する方法および組成物
JP2009500425A (ja) エスゾピクロン及びトランス4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロ−n−メチル−1−ナフタレンアミン又はトランス4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロ−1−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
EP3197445B1 (en) Proline or proline derivatives for the treatment of dementia
WO2011153929A1 (zh) 淫羊藿苷和含有淫羊藿苷的淫羊藿黄酮的新用途
CN113710319A (zh) 用于治疗焦虑相关病症的组合物和方法
JP2009500420A (ja) エスゾピクロン及びo−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
TWI250872B (en) Carbamate compounds for use in preventing or treating bipolar disorder
CN104013638B (zh) 当药黄素及其衍生物的用途
WO2020067333A1 (ja) 線維症治療用医薬組成物
US20110039926A1 (en) Use of enantiomer (1s, 2r) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
KR102668888B1 (ko) 섬유증의 예방 또는 치료용 조성물
CN111670041A (zh) 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
JP2024511676A (ja) 術後回復のためのオレキシン2受容体アゴニストの使用